CSCs resistant to KRAS-targeting therapy in the PDAC context, as well as leukemic stem cells (LSCs) resistant to BCR-ABL-targeting in chronic myeloid leukemia (CML), were found to express an OXPHOS phenotype [102,103]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.